Loading
Radiotherapy is given to half of all cancer patients but few new drugs are tested alongside it. A permanent trial platform would test drug-plus-radiation pairs systematically.
Radiosensitisers and immune-radiation combinations have strong biological rationale but almost no industry sponsorship because radiotherapy is unpatentable. The CONCORDE platform in the UK tests DNA-damage-response inhibitors with thoracic radiotherapy. Extending the model to a standing multi-tumour radiotherapy-drug platform with dose-finding modules and a shared radiotherapy quality-assurance backbone would fill a systematic gap.
Shares Too many combinations to test, Cancer Research UK, Glioma & glioblastoma.
Shares Too many combinations to test, Head and neck squamous cell carcinoma.
Shares NRG Oncology, Surgery and radiotherapy cure most, get least.